ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated statistically significant and clinically meaningful improvement in PFS as 1st-line treatment of patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial
AstraZeneca and Daiichi Sankyo announced positive top-line results from the DESTINY-Lung04 Phase III trial, showing ENHERTU demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) as a first-line treatment for HER2-mutant advanced non-small cell lung cancer (NSCLC). The trial compared ENHERTU against the global standard of care—platinum-pemetrexed doublet chemotherapy plus pembrolizumab—and is the first Phase III trial to show a PFS benefit for a HER2-directed therapy in this setting.
Key figures
- Her2 mutant prevalence
- 2-4% of patients with NSCLC
- Global lung cancer cases 2024
- 2.6 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.